ASH 2022 | Validation of the IPSS-M risk stratification system in MDS
Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, addresses the novel Molecular International Prognostic Scoring System (IPSS-M), and describes a study validating its use in the risk stratification of patients with myelodysplastic syndromes (MDS). Patients previously classified using the Revised International Prognostic Scoring System (IPSS-R) were re-classified using the IPSS-M, which gave accurate predictions of leukemia-free and overall survival (OS). Dr Komrokji also highlights the need to address how reclassification with the IPSS-M may impact treatment strategies. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Jazz: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Honoraria, Other, Speakers Bureau; CTI biopharma: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Geron: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Taiho: Honoraria, Membership on an entity’s Board of Directors or advisory committees.
